PCN142 Methodological Limitations of Patient-Reported Outcome Measures (PROMs) in oncology: A Meta-Review

Abstract

of patients at the basal and final visits respectively. 93% (nϭ240) of patients received chemotherapy in first line and 78.2% received targeted therapies (mainly erlotinib) as second line therapies. Twenty-six percent of patients demonstrated disease progression at the final visit but FACT-L scores showed no difference between visits; 48.8% of patients reported unchanged perceived health status and 28.1% reported an improvement. Patient and physician LCSS scores showed 86.4% of patients reported more symptoms than their physician but that there were no differences between visits. The impact of symptoms on daily life was slightly lower at the final than the basal visit. Statistically significant differences were observed between disease progression and the impact of cough (p ϭ 0.040) and pain (p ϭ 0.02), and also between the LCSS scale score (p Ͻ0.01). CONCLUSIONS: Stability and improvement of some symptoms corresponded to lower impact of the same symptoms on patients. The number and type of symptoms were related to HRQoL and the degree to which patient daily life was affected.